# Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT00317811** · PHASE2 · COMPLETED · sponsor: **Oncotherapeutics** · enrollment: 35 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DIETARY_SUPPLEMENT:** ascorbic acid
- **DRUG:** bortezomib
- **DRUG:** melphalan

## Key facts

- **NCT ID:** NCT00317811
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317811, "Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00317811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*